Casma Therapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
29
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$75M
- Investors
-
13
Casma Therapeutics General Information
Description
Developer of natural cellular process of autophagy designed to open new target areas for drug discovery and development. The company's focus is on the autophagy system to improve the cellular process of clearing out unwanted proteins, organelles, and invading pathogens, it also arrests or reverses the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders, and neurodegeneration, enabling physicians to address unmet medical needs and to bring cures to patients with serious diseases.
Contact Information
Website
www.casmatx.comCorporate Office
- 400 Technology Square
- Suite 201
- Cambridge, MA 02139
- United States
Corporate Office
- 400 Technology Square
- Suite 201
- Cambridge, MA 02139
- United States
Casma Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series C) | 07-Jul-2022 | $75M | Completed | Generating Revenue | ||
| 3. Early Stage VC (Series B) | 10-Sep-2020 | Completed | Generating Revenue | |||
| 2. Grant | 29-May-2019 | $370K | $58.5M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 03-May-2018 | $58.5M | $58.5M | Completed | Startup |
Casma Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 58,675,000 | $0.001000 | $1 | $1 | 1x | $1 | 18.24% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Casma Therapeutics Comparisons
Industry
Financing
Details
Casma Therapeutics Competitors (49)
One of Casma Therapeutics’s 49 competitors is iOmx Therapeutics, a Venture Capital-Backed company based in Munich, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| iOmx Therapeutics | Venture Capital-Backed | Munich, Germany | ||||
| PAQ Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Recyte Therapeutics | Formerly VC-backed | Alameda, CA | ||||
| Aitia | Venture Capital-Backed | Somerville, MA | ||||
| Egenesis | Venture Capital-Backed | Cambridge, MA |
Casma Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Casma Therapeutics Patents
Casma Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4192957-A2 | Trpml modulators | Pending | 07-Aug-2020 | ||
| US-20230416262-A1 | Trpml modulators | Pending | 07-Aug-2020 | ||
| EP-4192957-A4 | Trpml modulators | Pending | 07-Aug-2020 | ||
| US-20230272392-A1 | Methods of tfeb activation and lysosomal biogenesis and compositions therefor | Pending | 03-Aug-2020 | ||
| EP-4188451-A1 | Methods of tfeb activation and lysosomal biogenesis and compositions therefor | Pending | 03-Aug-2020 | A61P3/00 |
Casma Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Casma Therapeutics Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Amgen Ventures | Corporate Venture Capital | Minority | ||
| Astellas Venture Management | Corporate Venture Capital | Minority | ||
| Eisai | Corporate Venture Capital | Minority | ||
| Euclidean Capital | Family Office | Minority | ||
| Mirae Asset Capital | Venture Capital | Minority |
Casma Therapeutics FAQs
-
When was Casma Therapeutics founded?
Casma Therapeutics was founded in 2018.
-
Where is Casma Therapeutics headquartered?
Casma Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Casma Therapeutics?
Casma Therapeutics has 29 total employees.
-
What industry is Casma Therapeutics in?
Casma Therapeutics’s primary industry is Drug Discovery.
-
Is Casma Therapeutics a private or public company?
Casma Therapeutics is a Private company.
-
What is the current valuation of Casma Therapeutics?
The current valuation of Casma Therapeutics is .
-
What is Casma Therapeutics’s current revenue?
The current revenue for Casma Therapeutics is .
-
How much funding has Casma Therapeutics raised over time?
Casma Therapeutics has raised $183M.
-
Who are Casma Therapeutics’s investors?
Amgen Ventures, Astellas Venture Management, Eisai, Euclidean Capital, and Mirae Asset Capital are 5 of 13 investors who have invested in Casma Therapeutics.
-
Who are Casma Therapeutics’s competitors?
iOmx Therapeutics, PAQ Therapeutics, Recyte Therapeutics, Aitia, and Egenesis are some of the 49 competitors of Casma Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
